Global Liquid Biopsy For Cancer Diagnostics Market Data 2024, Forecast To 2033
8 Mar, 2024
The liquid biopsy for cancer diagnostics market has experienced rapid growth, rising from $7.82 billion in 2023 to $9.17 billion in 2024, with a significant compound annual growth rate (CAGR) of 17.3%. Advancements in genomic research and increased cancer prevalence contribute to this growth. Forecasts suggest further rapid growth, reaching $16.42 billion in 2028, with a CAGR of 15.7%. Integration into routine diagnostics and early cancer detection are anticipated to drive this expansion. Major trends include multi-omics approaches and AI integration.
Global Liquid Biopsy For Cancer Diagnostics Market Key Driver
The rising incidence of cancer is poised to drive the growth of the liquid biopsy for cancer diagnostics market. With approximately 1.8 million new cancer cases diagnosed in the US in 2020, there's an increasing need for accurate and non-invasive diagnostic procedures. Liquid biopsies offer real-time information on tumor evolution, therapeutic targets, and resistance mechanisms, making them valuable in cancer diagnosis and treatment monitoring. Consequently, the rising incidence of cancer is a significant driver for the liquid biopsy for cancer diagnostics market.
Get A Free Sample Of The Global Liquid Biopsy For Cancer Diagnostics Market ReportGlobal Liquid Biopsy For Cancer Diagnostics Market Segments
The liquid biopsy for cancer diagnostics market covered in this report is segmented –
1) Type:Product, Services
2) Sample:Blood, Urine, Saliva
3) Cancer:Lung Cancer, Breast Cancer, Colon Cancer, Other Cancers
4) End-User:Hospitals, Diagnostic Centers, Other End-Users
By Geography: The countries covered in the liquid biopsy for cancer diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
North America was the largest region in the liquid biopsy for cancer diagnostics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the liquid biopsy for cancer diagnostics market report during the forecast period. The regions covered in the liquid biopsy for cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Major Liquid Biopsy For Cancer Diagnostics Industry Players
F. Hoffman La Roche Ltd.; Thermo Fisher Scientific Inc.; Agilent Technologies Inc.; Illumina Inc.; The Menarini Group; Bio-Rad Laboratories Inc.; QIAGEN Inc.; Exact Sciences Corporation; Bio-Techne Corporation; ArcherDX Inc.; Neogenomics Laboratories Inc.; Guardant Health Inc.; Myriad Genetics Inc.; Foundation Medicine Inc.; Amoy Diagnostics Co. Ltd.; Biocartis Group NV; Biodesix Inc.; MDx Health Inc.; Sysmex Inostics Inc.; Biocept Inc.; Agena Bioscience Inc.; Laboratory for Advanced Medicine (LAM) Inc.; MiRXES Pte Ltd.; Inivata Limited; Resolution Bioscience Inc.; SAGA Diagnostics AB; NuProbe Inc.; Personal Gemone Diagnostics Inc.; Pathway Genomics Corporation; Angle PLC
Get The Full Global Liquid Biopsy For Cancer Diagnostics Market Report
Liquid Biopsy For Cancer Diagnostics Market Overview
Liquid biopsy for cancer diagnostics is a less invasive method than traditional tissue biopsies, which include evaluating genetic material or biomarkers discovered in a patient's blood or other bodily fluids to find and monitor the presence of cancer. It is commonly used for screening and identifying non-small cell lung cancer (NSCLC) and as a gastrointestinal and ovarian liquid biopsy for cancer diagnostics.